Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating
Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating
Maxim将Dermata Therapeutics的目标股价从16美元调低至4美元,维持买入评级。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册